Together, these findings suggest that the NLRP3 inflammasome, HMGB1, TLR4, and possibly some other mediators might serve as promising therapeutic targets to counter visfatin-mediated vascular injury associated to obesity. This evidence concerns the gene NAMPT and obesity due to melanocortin 4 receptor deficiency.